These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Purtscher retinopathy and necrotizing vasculitis with gemcitabine therapy. Banach MJ; Williams GA Arch Ophthalmol; 2000 May; 118(5):726-7. PubMed ID: 10815173 [No Abstract] [Full Text] [Related]
24. Pulmonary toxicity associated with gemcitabine. Saif MW JOP; 2010 Mar; 11(2):189-90. PubMed ID: 20208334 [No Abstract] [Full Text] [Related]
25. Gemcitabine-Induced Subacute Cutaneous Lupus Erythematosus: A Case Report. Ben Zvi M; Vaknine H; Menczer J; Peled O; Ben Shem E; Schreiber L; Levy T Chemotherapy; 2016; 61(5):236-9. PubMed ID: 26928175 [TBL] [Abstract][Full Text] [Related]
26. Side effects of chemotherapy. Case 3. Acute interstitial pneumonitis related to gemcitabine. Attar EC; Ervin T; Janicek M; Deykin A; Godleski J J Clin Oncol; 2000 Feb; 18(3):697-8. PubMed ID: 10653887 [No Abstract] [Full Text] [Related]
27. Gemcitabine hydrochloride: combination of activity and tolerability. Proceedings of a symposium. Jerusalem, Israel, November 14, 1993. Anticancer Drugs; 1995 Dec; 6 Suppl 6():5-65. PubMed ID: 8718418 [No Abstract] [Full Text] [Related]
29. Hemolytic-uremic syndrome caused by gemcitabine. Nackaerts K; Daenen M; Vansteenkiste J; Vandevelde A; Van Bleyenbergh P; Demedts M Ann Oncol; 1998 Dec; 9(12):1355. PubMed ID: 9932169 [No Abstract] [Full Text] [Related]
30. Veno-occlusive disease of the liver induced by gemcitabine. Dobbie M; Hofer S; Oberholzer M; Herrmann R Ann Oncol; 1998 Jun; 9(6):681. PubMed ID: 9681086 [No Abstract] [Full Text] [Related]
31. [Severe ischemic myopathy localized in an irradiated area following gemcitabine therapy]. Pariente A; Berthelémy P; Arotçarena R; Bénichou M; Calès V; Dujols JP Presse Med; 2000 Oct; 29(30):1650. PubMed ID: 11089501 [No Abstract] [Full Text] [Related]
32. Gemcitabine: a phase II study in patients with advanced renal cancer. De Mulder PH; Weissbach L; Jakse G; Osieka R; Blatter J Cancer Chemother Pharmacol; 1996; 37(5):491-5. PubMed ID: 8599874 [TBL] [Abstract][Full Text] [Related]
33. Dramatic improvement of psoriasis with gemcitabine monotherapy. Landi D; Santini D; Vincenzi B; La Cesa A; Dianzani C; Tonini G Br J Dermatol; 2003 Dec; 149(6):1306-7. PubMed ID: 14674923 [No Abstract] [Full Text] [Related]
34. Gemcitabine-related "pseudocellulitis": report of 2 cases and review of the literature. Tan DH; Bunce PE; Liles WC; Gold WL Clin Infect Dis; 2007 Sep; 45(5):e72-6. PubMed ID: 17682983 [TBL] [Abstract][Full Text] [Related]
35. Coadministration of 5% glucose solution relieves vascular pain in the patients administered gemcitabine immediately. Hosokawa A; Nakashima T; Ogawa Y; Kozawa K; Kiba T J Oncol Pharm Pract; 2013 Jun; 19(2):190-2. PubMed ID: 22733838 [No Abstract] [Full Text] [Related]
36. An unusual case of gemcitabine-induced radiation recall. Squire S; Chan M; Feller E; Mega A; Gold R Am J Clin Oncol; 2006 Dec; 29(6):636. PubMed ID: 17149004 [No Abstract] [Full Text] [Related]
37. Gemcitabine for pancreatic cancer: how hard to look for clinical benefit? An American perspective. Gelber RD Ann Oncol; 1996 Apr; 7(4):335-7. PubMed ID: 8805922 [No Abstract] [Full Text] [Related]
38. Clinical and preclinical activity of 2',2'-difluorodeoxycytidine (gemcitabine). Lund B; Kristjansen PE; Hansen HH Cancer Treat Rev; 1993 Jan; 19(1):45-55. PubMed ID: 8431926 [No Abstract] [Full Text] [Related]
39. Setting the record straight: activity of gemcitabine monotherapy for breast cancer. Reichardt P; Miles D Oncology; 2004; 66(4):339-40; author reply 341-2. PubMed ID: 15218304 [No Abstract] [Full Text] [Related]